Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes

Neurobiology of Disease
C MarinJose A Obeso

Abstract

Coadministration of entacapone with levodopa attenuates motor complications in experimental models of Parkinson's disease. The mechanisms underlying entacapone effects are unknown. We investigated the effect of entacapone, on: long-duration response (LDR) to levodopa, levodopa-induced postsynaptic pharmacodynamic mechanisms and molecular changes in hemiparkinsonian rats. 6-Hydroxydopamine-unilaterally lesioned rats were treated with levodopa (25 mg/kg)+vehicle; levodopa+entacapone (30 mg/kg) or saline, twice daily for 22 days. The LDR and the apomorphine-induced rotations were measured. In situ hybridization was performed measuring the expression of striatal preproenkephalin, preprodynorphin and dopamine D-3 receptor mRNAs, subthalamic cytochrome oxidase mRNA and nigral glutamic acid decarboxylase mRNA. Entacapone potentiated the LDR but did not modify either the apomorphine-induced rotational behavior or the molecular changes. Our results suggest that the effects of entacapone on levodopa-induced motor response are not mediated by postsynaptic mechanisms and that administration of entacapone is not able to normalize the molecular alterations induced by levodopa in the basal ganglia.

References

Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Aug 1, 1995·Neurology·J G NuttW R Woodward
Jan 1, 1996·Journal of Neurology, Neurosurgery, and Psychiatry·H M Ruottinen, U K Rinne
Oct 29, 2000·Trends in Neurosciences·F CalonP J Bédard
Jan 23, 2003·The Journal of Pharmacology and Experimental Therapeutics·Markus ForsbergPekka T Männistö
Jan 14, 2004·Neurology·Fabrizio Stocchi, C Warren Olanow
Feb 13, 2004·Brain : a Journal of Neurology·Raúl de la Fuente-FernándezA Jon Stoessl
Oct 27, 2004·Naunyn-Schmiedeberg's Archives of Pharmacology·Manfred GerlachPeter Riederer
Jan 27, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Concepció MarinJosé A Obeso
Mar 17, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Fabrizio GardoniPaolo Calabresi
May 11, 2006·Brain : a Journal of Neurology·F Alonso-FrechJ A Obeso
Apr 13, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Giovanni FabbriniChristopher G Goetz
May 23, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Günther DeuschlUNKNOWN CAMP Study Group

❮ Previous
Next ❯

Citations

Apr 20, 2011·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·L-S LiJ-X Zhu
Jun 4, 2014·Contrast Media & Molecular Imaging·Aida Niñerola-BaizánDomènec Ros

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.